Healthcare
•3753 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3753)
| Company | Market Cap | Price |
|---|---|---|
|
PRGO
Perrigo Company plc
OTC Pain Relief & Analgesics are a core OTC category (e.g., Solpadeine) in Perrigo's portfolio.
|
$2.07B |
$15.02
-1.02%
|
|
SRPT
Sarepta Therapeutics, Inc.
Directly develops gene therapies (ELEVIDYS) and other gene therapy programs; gene therapy is Sarepta's core biotech focus.
|
$2.06B |
$21.13
-0.84%
|
|
AORT
Artivion, Inc.
Artivion's core business is manufacturing medical devices and implantable tissues across cardiology and vascular platforms.
|
$2.05B |
$43.31
+0.05%
|
|
ZLAB
Zai Lab Limited
Core oncology focus across a deep late-stage pipeline including multiple oncology antibodies and ADC assets.
|
$2.04B |
$18.57
-1.33%
|
|
SGRY
Surgery Partners, Inc.
Operates outpatient surgery centers and ASCs, the core service offering and revenue driver.
|
$2.04B |
$15.90
-0.62%
|
|
RXRX
Recursion Pharmaceuticals, Inc.
Collaborations with pharma partners and outsourced discovery work resemble a CRO-type service model.
|
$2.03B |
$4.66
+0.43%
|
|
OSW
OneSpaWorld Holdings Limited
Medi-Spa offerings utilize medical devices and biometrics (e.g., CoolSculpting Elite, Elemis Biotec, LightStim).
|
$2.03B |
$19.75
-2.16%
|
|
MESO
Mesoblast Limited
Direct product category: allogeneic mesenchymal lineage cell therapy platform and approved product Ryoncil.
|
$2.01B |
$17.47
-1.47%
|
|
NEOG
Neogen Corporation
MDS pathogen detection platform and Petrifilm-based environmental testing are diagnostic equipment offerings.
|
$2.01B |
$9.24
-2.27%
|
|
UFPT
UFP Technologies, Inc.
Design and manufacture of customized components and subsystems used in medical devices (foams, films, plastics, fabrics, die-cut parts, and assembly).
|
$2.01B |
$260.62
+1.27%
|
|
SYRE
Spyre Therapeutics, Inc.
Spyre's pipeline comprises engineered monoclonal antibodies (SPY001/SPY002/SPY003) targeting α4β7, TL1A, and IL-23 for IBD and RA.
|
$2.01B |
$33.26
+0.51%
|
|
NUVB
Nuvation Bio Inc.
Core oncology focus with IBTROZI and safusidenib as oncology therapies, fitting Biotech - Oncology.
|
$2.00B |
$5.84
-4.80%
|
|
LMAT
LeMaitre Vascular, Inc.
Directly produces vascular interventional devices (grafts, patches, shunts, catheters) used in vascular surgery.
|
$2.00B |
$88.45
+2.25%
|
|
UCTT
Ultra Clean Holdings, Inc.
Provides laboratory testing and advisory services relevant to semiconductor manufacturing cleanliness and optimization.
|
$1.98B |
$43.72
+0.83%
|
|
ADUS
Addus HomeCare Corporation
Core service line providing Home Health & Hospice care in-home.
|
$1.98B |
$107.38
-2.20%
|
|
OCUL
Ocular Therapeutix, Inc.
ELUTYX is a proprietary drug-delivery platform central to Ocular Therapeutix's retina-focused pipeline.
|
$1.96B |
$11.27
-0.13%
|
|
ESTA
Establishment Labs Holdings Inc.
Motiva implants, tissue expanders, and related breast prosthetic devices are the core product line, i.e., prosthetics & implants.
|
$1.96B |
$67.44
+2.24%
|
|
AUPH
Aurinia Pharmaceuticals Inc.
LUPKYNIS is an oral small-molecule therapeutic, and Aurinia's AUR200 program reflects a focus on oral small-molecule therapeutics in its pipeline.
|
$1.95B |
$14.86
-0.10%
|
|
IMNM
Immunome, Inc.
Primary modality across the pipeline is Antibody-Drug Conjugates (ADCs).
|
$1.95B |
$22.43
-1.86%
|
|
ATRC
AtriCure, Inc.
AtriCure directly manufactures surgical equipment and devices used in operating rooms and minimally invasive cardiac procedures.
|
$1.94B |
$39.09
-5.72%
|
|
AVAH
Aveanna Healthcare Holdings Inc.
AVAH directly provides Home Health and Hospice services to patients in home settings.
|
$1.93B |
$9.21
-5.58%
|
|
SEM
Select Medical Holdings Corporation
Direct hospital services provider; SEM's core revenue comes from Hospital Services including inpatient rehabilitation and CIRH.
|
$1.90B |
$15.37
-0.36%
|
|
MD
Pediatrix Medical Group, Inc.
Provides hospital-based neonatal and maternal-fetal care services (NICU care and maternal-fetal medicine) delivered in hospital settings.
|
$1.90B |
$21.86
-3.55%
|
|
VCEL
Vericel Corporation
Vericel's core offerings are autologous cell therapies (MACI and Epicel), placing the company in the cell therapy space.
|
$1.89B |
$37.45
-2.90%
|
|
SKWD
Skyward Specialty Insurance Group, Inc.
Accident & Health activities include health insurance lines (group stop-loss and related A&H offerings).
|
$1.88B |
$46.45
-0.05%
|
|
OLMA
Olema Pharmaceuticals, Inc.
Olema is a biotechnology company focused on oncology therapies, including palazestrant in ER+ breast cancer.
|
$1.86B |
$27.14
-7.04%
|
|
ANIP
ANI Pharmaceuticals, Inc.
ANI's Rare Disease/Brands expansion includes ophthalmic therapies ILUVIEN and YUTIQ acquired via Alimera, marking Ophthalmic Drugs as a direct product category.
|
$1.84B |
$84.85
-0.52%
|
|
AZTA
Azenta, Inc.
Azenta's automated sample storage and cryogenic systems fall under Medical Devices & Biometrics.
|
$1.83B |
$40.01
+0.25%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.83B |
$15.62
|
|
MAZE
Maze Therapeutics, Inc.
Maze develops small molecule therapeutics, including MZE829 and MZE782, which are oral small molecule treatments for renal/cardiovascular/metabolic diseases.
|
$1.79B |
$40.85
+2.61%
|
|
BHE
Benchmark Electronics, Inc.
Manufactures Medical Device Components for use in regulated medical devices.
|
$1.78B |
$49.50
-0.06%
|
|
HROW
Harrow Health, Inc.
Strategic biosimilars portfolio in ophthalmology (BYOOVIZ, OPUVIZ) with Samsung Bioepis.
|
$1.77B |
$47.88
-1.26%
|
Showing page 11 of 38 (3753 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
